Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CKD-314 (Nafabelltan) in Hospitalized COVID-19 Pneumonia
NCT04623021Phase 2Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Sep 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in COVID-19 pneumonia comparing Standard of Care with Nafabelltan + SOC (2 arms). Primary endpoint: Time to clinical improvement at 28 days. Started Sep 2020; status: completed.
02
Drugs
Nafabelltan
03
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04623021.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04623021.